lncRNA expression analysis in patients with eosinophilic and neutrophilic asthma. lncRNA expression analysis in patients with eosinophilic and neutrophilic asthma

Long non-coding RNA (lncRNA) are known to be important in many diseases. There has been some reports that lncRNA take part in the pathogenesis of systemic inflammation of asthma. lncRNA regulates gene transcription, protein expression and epigenetic regulation. However, the lncRNAs associated with differently airway phenotype such as eosinophilic and neutrophilic asthma remains unknown. We aimed at identifying the differences in circulating lncRNA signature in Eos and Neu samples. lncRNA expression were studied between blood samples from Eos patients, Neu patients and healthy individuals (Control). Bioinformatic analysis was used to describe relevant biological pathways. Using quantitative real-time PCR, lncRNA expression was measured. Comparing with Control samples, Eos sample has 190 own lncRNA and Neu sample has 166 own lncRNA(difference ≥ 2-fold). KEGG pathway annotation data and GO terms revealed that several lncRNAs are possibly associated with respective phenotype. lncRNA was identifying to differ significantly between Eos and Neu samples by using qRT-PCR. The results show us that lncRNA may be involved in different phenotypes of asthma. Whether we can recognize different phenotypes of asthma through these lncRNA (as biomarkers) needs further study. Overall design: Patients with eosinophilic asthma (Eos, n = 12) and neutrophilic asthma (Neu, n = 6) were selected in the study according the accepted standard (Eos: induced sputum eosinophil count >3% and neutrophils 63% )1. Exclusion criteria contained recent (within the past weeks) respiratory tract infection, recent unstable asthma, recent asthma exacerbation, current smoking (or a history of smoking, within 6 months of cessation), and changes in maintenance therapy. All participants were selected from the People’s Liberation Army General Hospital, and all participants have been given informed consent before their inclusion. Healthy individuals were selected as Control samples (n = 6). The results show us that lncRNA may be involved in different phenotypes of asthma. Whether we can recognize different phenotypes of asthma through these lncRNA (as biomarkers) needs further study. This dataset is related to GSE106230

长链非编码RNA（long non-coding RNA，lncRNA）已被证实于多种疾病中发挥重要调控作用。已有研究报道，lncRNA参与哮喘全身性炎症的发病过程。lncRNA可调控基因转录、蛋白质表达及表观遗传修饰。然而，与嗜酸性粒细胞性、中性粒细胞性哮喘等不同气道表型相关的lncRNA仍未明确。本研究旨在鉴定嗜酸性粒细胞性哮喘（Eos）与中性粒细胞性哮喘（Neu）样本中循环lncRNA特征谱的差异。研究人员对嗜酸性粒细胞哮喘患者、中性粒细胞哮喘患者及健康个体（对照组）的血液样本进行了lncRNA表达分析。采用生物信息学分析阐释相关生物学通路，并通过定量实时聚合酶链反应（quantitative real-time PCR，qRT-PCR）检测lncRNA的表达水平。与对照组样本相比，嗜酸性粒细胞哮喘样本存在190种特异性lncRNA，中性粒细胞哮喘样本存在166种特异性lncRNA（表达差异≥2倍）。京都基因与基因组百科全书通路（Kyoto Encyclopedia of Genes and Genomes pathway，KEGG）注释数据及基因本体论（Gene Ontology，GO）条目分析显示，多种lncRNA可能与各自对应的哮喘表型相关。通过qRT-PCR验证发现，嗜酸性粒细胞哮喘与中性粒细胞哮喘样本间的lncRNA表达存在显著差异。研究结果表明，lncRNA可能参与哮喘的不同表型进程。通过此类lncRNA作为生物标志物区分哮喘不同表型的可行性，仍需进一步研究验证。总体实验设计：本研究按照公认标准筛选受试者：嗜酸性粒细胞性哮喘患者（Eos，n=12）的筛选标准为诱导痰嗜酸性粒细胞计数＞3%且中性粒细胞占比63%¹；中性粒细胞性哮喘患者（Neu，n=6）。排除标准包括：近期（过去数周内）呼吸道感染、近期不稳定型哮喘、近期哮喘急性发作、当前吸烟（或6个月内有吸烟史且已戒烟）以及维持治疗方案发生变更。所有研究对象均招募自中国人民解放军总医院，且入组前均已签署知情同意书。健康个体作为对照组样本（n=6）。本研究结果再次显示，lncRNA可能参与哮喘的不同表型进程。通过此类lncRNA作为生物标志物区分哮喘不同表型的可行性，仍需进一步研究验证。本数据集与GSE106230相关。